China’s life sciences and healthcare (LS&H) industry underwent an unprecedented transformation in 2023. Fangda Partners’ leading life sciences team advised on many of the market’s most important LS&H transactions, gaining great insight into the industry’s challenges and opportunities. They sum up these changes in an article written for the 2024 Life Sciences Yearbook, China life sciences: transaction insights and notable industry trends, as well as taking part in a Q&A session for Legal 500 and Legal Business Magazine. In the article, our LS&H partners Josh Wei Shin, Henry He, Junting Yin and associate Audrey Luo introduce the key takeaways and considerations for China LS&H transactions and share their observations of, and strategies for, concluding China LS&H transactions. In the Q&A, Josh Shin, Henry He and counsel Moqiu (Muriel) He use 10 Q&As to provide readers with a comprehensive understanding about the current regulatory frameworks governing the life sciences industry in China, all the key issues that matter to China and foreign life sciences companies doing business in China, as well as legal challenges and opportunities related to emerging fields within the industry. Here is the online version of the article and the Q&A part, respectively, on Legal500.com: https://lnkd.in/gtdNBHHr https://lnkd.in/gThRGTs8